KANO BIO
Dead / Abandoned — Abandoned — no statement of use filed (as of 21 Oct 2024)
What this means for you
This application is over — abandoned 21 Oct 2024. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97700220
- Mark type
- Stylized text
- Filed
- 01 Dec 2022
- Published for opposition
- 23 Jan 2024
- Abandoned
- 21 Oct 2024
- Attorney of record
- Rocky Cislak
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for single-stranded DNA; Biologics, namely, nucleic acids for use as therapeutics for clinical and medical use
- Class 040 — Treatment of materials: Custom manufacturing of nucleic acids for diagnostic, medical and commercial applications in relation to cell and gene therapies; Custom manufacturing of nucleic acids, biological organisms and components and products thereof in the nature of therapeutics for pharmaceutical drug development; Manufacturing services for others, namely, manufacture of synthetic DNA and genes; Custom manufacturing, namely, synthesis of pharmaceuticals
- Class 042 — Scientific and technological services: Pharmaceutical drug development services; Scientific research and development of synthesis of pharmaceuticals; Scientific research and development; Pharmaceutical, medical, scientific, and biopharmaceutical research and development; Biochemical research and development services, namely, custom development and synthesis of nucleic acids, biological organisms, and components and products thereof for pharmaceutical drug development; Design and development in the field of custom synthesis of cells and vectors for diagnostic, medical and commercial applications in relation to the design of nucleic acids and genetic medicines; Bioinformatic design of genetically engineered organisms; Research, design, and development of genetically engineered organisms; Product development consultation in the fields of pharmaceutical, medical, scientific, and biopharmaceutical research and development; Product development in the fields of products for pharmaceutical drug development; Research and development in the field of pharmaceuticals; Research and design services relating to pharmaceuticals; Research in the field of pharmaceutical preparations
Owner
- Kano Therapeutics Inc., Cambridge, MA, US
- Kano Therapeutics Inc., Cambridge, MA, US
Prosecution history
- 21 Oct 2024 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 21 Oct 2024 — ABANDONMENT - NO USE STATEMENT FILED
- 19 Mar 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 23 Jan 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 23 Jan 2024 — PUBLISHED FOR OPPOSITION
- 03 Jan 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 14 Dec 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 13 Dec 2023 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 12 Dec 2023 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 12 Dec 2023 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 13 Sept 2023 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 13 Sept 2023 — NON-FINAL ACTION E-MAILED
- 13 Sept 2023 — NON-FINAL ACTION WRITTEN
- 11 Sept 2023 — ASSIGNED TO EXAMINER
- 22 Mar 2023 — TEAS CHANGE OF CORRESPONDENCE RECEIVED